Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The PRINCIPLE Trial has led the way in evaluating treatments for COVID-19 in the community over the last two years.

A time line image of the milestones that have been reached in the first two years of the PRINCIPLE Trial
PRINCIPLE milestones over the last two years

The PRINCIPLE Trial has led the way in evaluating treatments for COVID-19 in the community over the past two years. It has tested five potential treatments so far, with a further two, favipiravir and ivermectin, still being studied in the trial.

PRINCIPLE was designed to rapidly identify treatments that showed promise and rule out treatments that did not work. Early on in the pandemic, the antibiotics azithromycin and doxycycline were being widely used around the world to treat acute COVID-19;  PRINCIPLE was the first major trial in the community to show that, in the absence of other indications, these antibiotics did not benefit COVID patients and so merely put them at unnecessary risk of side effects and added to the problem of antibiotic resistance.

PRINCIPLE also found that the anti-inflammatory drug, colchicine, did not help people get better any quicker.

 A key finding from the Trial announced in April 2021 was that the commonly used asthma drug, inhaled Budesonide, a steroid, was effective in reducing recovery time by around three days and that there was a high probability that it also reduced hospital admission.

The Platform Randomised trIal of treatmeNts in the Community for epIdemic and Pandemic iLlnEsses (PRINCIPLE) Trial is led by the University of Oxford and funded by UK Research and Innovation (UKRI) and National Institute for Health Research (NIHR).

Similar stories

Primary care research nurses nominated for OUH Award

Congratulations to the amazing team of research nurses working in the Primary Care Clinical Trials Unit who have been shortlisted as finalists in the Oxford University Hospitals NHS Foundation Trust Staff Recognition Awards 2021.

10,000 people join the PRINCIPLE Trial – A huge ‘Thank You’ from us all.

10,000 people have joined the PRINCIPLE Trial over the last two years and we want to say a big ‘Thank You’ to them all for their amazing contribution to testing treatments for COVID-19 in the community.

British Muslim organisations support PANORAMIC ahead of Ramadan

The Muslim Council of Britain (MCB) and the British Islamic Medical Association (BIMA) joined forces in March to help promote the PANORAMIC trial as part of a series of outreach activities ahead of the Muslim holy month of Ramadan, enabling greater outreach to diverse communities across Britain.

PANORAMIC hits the 20,000 participant milestone

The world’s largest study of community-based treatments for acute COVID-19 has reached a world-first, historic milestone: over twenty thousand participants from across the UK have now taken part in the PANORAMIC trial.

PRINCIPLE trial 'highly commended' for innovative use of health data

The PRINCIPLE trial has been highly commended at the Health Data Research UK Awards for the way in which patient data is utilised so participants are contacted about the trial soon after receiving a positive test result.

PRINCIPLE Trial to strengthen Black, Asian and minority ethnic community participation

Professor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead